InsiderTrades

Form 4 for TXG 10x Genomics, Inc.

Accepted 2025-03-04 00:00:00 ET · period of report 2025-02-28 · accession 0001610717-25-000049 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-03-04 2025-03-04 TXG Saxonov Serge CEO, Dir M - OptEx $1.20 +50.0K 921.5K +6% +$60.0K
DT 2025-03-04 2025-02-28 TXG Saxonov Serge CEO, Dir S - Sale+OE $10.63 -7,942 871.5K -0.9% -$84.4K
DT 2025-03-04 2025-03-04 TXG Saxonov Serge CEO, Dir M - OptEx $0.00 -50.0K 17.5K -74% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2025-03-04 M A 50,000 $1.20 921,540 D — —
2 Common Class A Common Stock 2025-02-28 S D 7,942 $10.63 871,540 D — — (F2) This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Derivative Stock Option (right to buy) 2025-03-04 M D 50,000 $0.00 17,463 D $1.20 · — to 2027-10-18 50,000 Class A Common Stock (F7) This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.